Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
FDA Approves New Single-Tablet HIV Regimen, Triumeq

The U.S. Food and Drug Administration (FDA) has approved Triumeq, ViiV Healthcare's single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV. The tablet is comprised of the integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (Kivexa/Epzicom) and is the first single-tablet regimen to receive approval that does not contain tenofovir.

Published
26 August 2014
From
Aidsmeds.com
Protein tethers HIV and Ebola to cells

A family of proteins that helps viruses, such as HIV and Ebola, enter a cell also can block the release of those viruses. When HIV-1 or any virus infects a cell, it replicates and spreads to other cells. One type of cellular protein—T cell immunoglobulin and mucin domain, or TIM-1—has previously been shown to promote entry of some highly pathogenic viruses into host cells. Researchers have now discovered that the same protein possesses a unique ability to block the release of such viruses. The findings are published in the Proceedings of the National Academy of Sciences. “This is a surprising finding that provides new insights into our understanding of not only HIV infection, but also that of Ebola and other viruses,” says Shan-Lu Liu, associate professor of molecular microbiology and immunology at University of Missouri.

Published
26 August 2014
From
Futurity
The Big Picture of Small Molecules for Curing HIV Infection

Dr. David Margolis and Karine Dubé of The Martin Delaney Collaboratory of AIDS Researchers for Eradication explain one strategy being pursued by scientists as a possible way to cure HIV. After reading this, if you want to learn more check out this video on related research.

Published
22 August 2014
From
AVAC
Vault nanoparticles engineered at UCLA show promise for cancer treatment and possible HIV cure

UCLA scientists developed a method for placing bryostatin 1 in nanoscale vaults for safe delivery to cells, where it can activate latent HIV, enabling the virus to be eradicated.

Published
22 August 2014
From
UCLA press release
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

iCo Therapeutics Inc. ("iCo" or "the Company") today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

Published
22 August 2014
From
iCo Therapeutics press release
2000-Fold Drop in Latent Reservoir Needed for 1 Year Without ART

About a 2000-fold reduction in the HIV reservoir in resting CD4 cells may be needed to let most people stop antiretroviral therapy (ART) for a single year without rebound, according to results of a modeling study. Predicted large variations in rebound times after ART stops mean close monitoring will be required for this strategy.

Published
21 August 2014
From
International AIDS Society
Zambia: PMTCT Real Life Story

The pain of living through the loss of three children was enough to discourage Constance Mudenda from ever contemplating parenting. When she was pregnant, her greatest desire was to have a child born free of HIV, and now she will continue to mentor her daughter to ensure she is protected from acquiring HIV.

Published
21 August 2014
From
Times of Zambia
How HIV co-opts gut bacteria to pose as a familiar infection

One of the most effective methods used by HIV to evade control is to hide from the immune system. B-cells are crucial for controlling new infections, producing specific antibodies to attack it, which coat the surface of infected cells and tag them for destruction. But according to a study from Duke Medicine, published in Cell Host & Microbe, when HIV enters and begins replicating in the gut, the reaction of B cells is ineffective because the virus is able to pose as a “good” bacterium. Its gp41 surface protein - which is displayed on the surface of infected cells - looks like surface proteins on the cells of friendly gut bacteria.

Published
21 August 2014
From
The Conversation UK
HIV superinfection associated with accelerated viral load increase but has no impact on clinical disease progression

HIV superinfection has no impact on clinical disease progression, investigators report in the online edition of AIDS. Superinfection was associated with accelerated viral load increase and had a

Published
19 August 2014
By
Michael Carter
'Shock and kill' approach cures mice of HIV in world first

A combination of four drugs can flush out HIV-infected cells from hidden reservoirs in the body and kill them with a boost to the immune system, according to research published in the journal Cell today.

Published
18 August 2014
From
The Conversation

Filter by country